Novon Wegovy laskee BMI-arvoja jo 6-vuotiailla lapsilla

33 lähdettä
  • Novo Nordisk ilmoitti maanantaina, että Wegovy laski 6–11-vuotiaiden lasten BMI-arvoja 13,5 % 68 viikon aikana.
  • Tulokset julkaistiin päivä sen jälkeen, kun JAMA-tutkimus osoitti Eli Lillyn Zepboundin laskeneen teini-ikäisten BMI-arvoja 18,5 % 72 viikossa.
  • Hoidetut lapset kasvoivat noin 3,3 senttimetriä vähemmän kuin lumeryhmän lapset, ja WHO:n ohjeistus ei suosittele lihavuuslääkkeitä alle 9-vuotiaille.
Lähteet (33)
  1. 1 Wegovy® resulted in a BMI reduction of 10% or more in almost 80% of children with obesity aged 6 to under 12, compared to 0% with placebo in STEP Young trial, published in The New England Journal of Medicine www.novonordisk.com
  2. 2 Wegovy leads to ‘substantial' BMI decrease for children aged 6 to 11 years with obesity www.healio.com
  3. 3 Tirzepatide in Adolescents With Obesity: Research Summary jamanetwork.com
  4. 4 Lilly’s Obesity Drug Zepbound Helped Adolescents Lose Weight www.bloomberg.com
  5. 5 Nuevos datos abren el camino para el uso de medicamentos para bajar de peso en niños pequeños diario.mx
  6. 6 Weight-Loss Drugs for Elementary-Age Children Succeed in Study www.wsj.com
  7. 7 Novo says Wegovy shot works in childhood obesity pharmaphorum.com
  8. 8 Tirzepatide in Adolescents With Obesity: The SURMOUNT-ADOLESCENTS Randomized Clinical Trial jamanetwork.com
  9. 9 Tirzepatide in Adolescents With Obesity media.jamanetwork.com
  10. 10 Tirzepatide Cuts BMI in Adolescents With Obesity in Phase III Trial www.medpagetoday.com
  11. 11 CagriSema & Wegovy® at ObesityWeek® | Novo Nordisk U.S. www.novonordisk-us.com
  12. 12 Lilly to present new data across Zepbound, Foundayo ... investor.lilly.com
  13. 13 Tirzepatide confers ‘robust' weight loss for adolescents with obesity www.healio.com
  14. 14 Pediatric Obesity Pharmacotherapy media.jamanetwork.com
  15. 15 Semaglutide cuts BMI 13.5% in children aged 6 to 11 with obesity | Contemporary Pediatrics www.contemporarypediatrics.com
  16. 16 Semaglutide for the Treatment of Obesity in Children 6 to <12 Years of Age | NEJM www.nejm.org
  17. 17 Novo Nordisk Says Wegovy Reduces BMI in Children With Obesity in Phase 3 Trial www.fidelity.com
  18. 18 Lilly obesity drug shows promising results in teenagers in new study wowo.com
  19. 19 Efficacy and Safety of Tirzepatide Among Adolescents with Obesity: Results from SURMOUNT-ADOLESCENTS delta.larvol.com
  20. 20 Eli Lilly Reports 18.5% BMI Reduction With Tirzepatide in Adolescents - Pharmacally pharmacally.com
  21. 21 Weight-loss drug Wegovy shows promising results in children as young as 6, major study finds www.ynetnews.com
  22. 22 Lilly says its obesity drugs helped patients lose weight in clinical trials www.fidelity.com
  23. 23 News details www.novonordisk-us.com
  24. 24 Semaglutide for the Treatment of Childhood Obesity: Results of the STEP-YOUNG Trial delta.larvol.com
  25. 25 Lilly presents obesity drug data at ObesityWeek 2026 www.clinicaltrialvanguard.com
  26. 26 Novo Nordisk: Wegovy reduced BMI by 17.4% in children in Phase 3 trial au.marketscreener.com
  27. 27 Impact of Tirzepatide on Quality of Life in Adolescents with Obesity: SURMOUNT-ADOLESCENTS delta.larvol.com
  28. 28 Tirzepatide delivers major BMI reductions in teens with obesity curie.md
  29. 29 Semaglutide Lowers BMI 16 Points Versus Placebo in Children Aged 6 to 11 www.peptideandprotein.com
  30. 30 Injectable Wegovy lowers BMI among children with obesity www.healio.com
  31. 31 Novo Nordisk reports BMI reductions in children taking Wegovy www.ii.co.uk
  32. 32 Obesity & metabolic news: latest medical stories and why they matter | Medical Week Daily medicalweekdaily.com
  33. 33 Weight-Loss Drugs for Elementary-Age Children Succeed in Study -- WSJ www.moomoo.com